|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI
|
|
2
|
Kakeji Y, Ishikawa T, Suzuki S, Akazawa K,
Irino T, Miyashiro I, Ono H, Suzuki H, Tanabe S, Kadowaki S, et al:
A retrospective 5-year survival analysis of surgically resected
gastric cancer cases from the Japanese gastric cancer association
nationwide registry (2001–2013). Gastric Cancer. 25:1082–1093.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cancer Genome Atlas Research Network, .
Comprehensive molecular characterization of gastric adenocarcinoma.
Nature. 513:202–209. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Janjigian YY, Shitara K, Moehler M,
Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T,
Campos Bragagnoli A, et al: First-line nivolumab plus chemotherapy
versus chemotherapy alone for advanced gastric, gastro-oesophageal
junction, and oesophageal adenocarcinoma (CheckMate 649): A
randomised, open-label, phase 3 trial. Lancet. 398:27–40. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sato Y, Okamoto K, Kawano Y, Kasai A,
Kawaguchi T, Sagawa T, Sogabe M, Miyamoto H and Takayama T: Novel
biomarkers of gastric cancer: Current research and future
perspectives. J Clin Med. 12:46462023. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shitara K, Lordick F, Bang YJ, Enzinger P,
Ilson D, Shah MA, Van Cutsem E, Xu RH, Aprile G, Xu J, et al:
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive,
HER2-negative, untreated, locally advanced unresectable or
metastatic gastric or gastro-oesophageal junction adenocarcinoma
(SPOTLIGHT): A multicentre, randomised, double-blind, phase 3
trial. Lancet. 401:1655–1668. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kawakami H and Okamoto I: MET-targeted
therapy for gastric cancer: The importance of a biomarker-based
strategy. Gastric Cancer. 19:687–695. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shi T, Zhang Y, Wang Y, Song X, Wang H,
Zhou X, Liang K, Luo Y, Che K, Wang X, et al: DKK1 promotes tumor
immune evasion and impedes anti-PD-1 treatment by inducing
immunosuppressive macrophages in gastric cancer. Cancer Immunol
Res. 10:1506–1524. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kim HS, Kim JH and Jang HJ: Pathologic and
prognostic impacts of FGFR2 amplification in gastric cancer:
A meta-analysis and systemic review. J Cancer. 10:2560–2567. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gao Y, Zhang K, Xi H, Cai A, Wu X, Cui J,
Li J, Qiao Z, Wei B and Chen L: Diagnostic and prognostic value of
circulating tumor DNA in gastric cancer: A meta-analysis.
Oncotarget. 8:6330–6340. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lee JS, Won HS, Sun S, Hong JH and Ko YH:
Prognostic role of tumor-infiltrating lymphocytes in gastric
cancer: A systematic review and meta-analysis. Medicine
(Baltimore). 97:e117692018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nakamura K, Sugano H and Takagi K:
Carcinoma of the stomach in incipient phase: Its histogenesis and
histological appearances. Gan. 59:251–258. 1968.PubMed/NCBI
|
|
13
|
Feng F, Liu J, Wang F, Zheng G, Wang Q,
Liu S, Xu G, Guo M, Lian X and Zhang H: Prognostic value of
differentiation status in gastric cancer. BMC Cancer. 18:8652018.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zu H, Wang H, Li C and Xue Y:
Clinicopathologic characteristics and prognostic value of various
histological types in advanced gastric cancer. Int J Clin Exp
Pathol. 7:5692–5700. 2014.PubMed/NCBI
|
|
15
|
Association JGC: Japanese Classification
of Gastric Carcinoma 2017. 15th edition. Kanehara; Tokyo: 2017
|
|
16
|
Wang X, Deng J and Liang H: Well
differentiated carcinoma with a poor prognosis: A retrospective
analysis of papillary gastric adenocarcinoma. Surg Today.
51:1387–1396. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li HZ, Zhu HT, Chen YY, Zheng RS, Jin GF,
Du LB and Cheng XD: Five-year survival analysis of gastric cancer
from population-based cancer registration data in Zhejiang
province, China. Zhonghua Zhong Liu Za Zhi. 46:862–870. 2024.(In
Chinese). PubMed/NCBI
|
|
18
|
Kunisaki C, Akiyama H, Nomura M, Matsuda
G, Otsuka Y, Ono HA, Nagahori Y, Takahashi M, Kito F and Shimada H:
Clinicopathological properties of poorly-differentiated
adenocarcinoma of the stomach: Comparison of solid- and
non-solid-types. Anticancer Res. 26:639–646. 2006.PubMed/NCBI
|
|
19
|
Yasuda K, Adachi Y, Shiraishi N, Maeo S
and Kitano S: Papillary adenocarcinoma of the stomach. Gastric
Cancer. 3:33–38. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shin HD, Bang KB, Kang SH, Moon HS, Sung
JK, Jeong HY, Lee DK, Kim KB, Kim SM, Lee SW, et al: Clinical
outcome of endoscopic submucosal dissection for papillary type
early gastric cancer: A multicenter study. Gut Liver. 18:426–433.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim HS, Kim JH, Jang HJ, Han B and Zang
DY: Pathological and prognostic impacts of FGFR2 overexpression in
gastric cancer: A meta-analysis. J Cancer. 10:20–27. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hur JY, Chao J, Kim K, Kim ST, Kim KM,
Klempner SJ and Lee J: High-level FGFR2 amplification is associated
with poor prognosis and Lower response to chemotherapy in gastric
cancers. Pathol Res Pract. 216:1528782020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ooki A and Yamaguchi K: The beginning of
the era of precision medicine for gastric cancer with fibroblast
growth factor receptor 2 aberration. Gastric Cancer. 24:1169–1183.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yashiro M, Kuroda K, Masuda G, Okuno T,
Miki Y, Yamamoto Y, Sera T, Sugimoto A, Kushiyama S, Nishimura S,
et al: Clinical difference between fibroblast growth factor
receptor 2 subclass, type IIIb and type IIIc, in gastric cancer.
Sci Rep. 11:46982021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kunii K, Davis L, Gorenstein J, Hatch H,
Yashiro M, Di Bacco A, Elbi C and Lutterbach B: FGFR2-amplified
gastric cancer cell lines require FGFR2 and Erbb3 signaling for
growth and survival. Cancer Res. 68:2340–2348. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wainberg ZA, Enzinger PC, Kang YK, Qin S,
Yamaguchi K, Kim IH, Saeed A, Oh SC, Li J, Turk HM, et al:
Bemarituzumab in patients with FGFR2b-selected gastric or
gastro-oesophageal junction adenocarcinoma (FIGHT): A randomised,
double-blind, placebo-controlled, phase 2 study. Lancet Oncol.
23:1430–1440. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kang YK, Qin S, Lee KW, Oh SC, Kim IH, Kim
JG, Li Y, Yan Z, Li J, Bai LY, et al: Bemarituzumab plus mFOLFOX6
as first-line treatment in East Asian patients with
FGFR2b-overexpressing locally advanced or metastatic
gastric/gastroesophageal junction cancer: Subgroup of FIGHT final
analysis. Gastric Cancer. 27:1046–1057. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wainberg ZA, Kang YK, Lee KW, Qin S,
Yamaguchi K, Kim IH, Saeed A, Oh SC, Li J, Turk HM, et al:
Bemarituzumab as first-line treatment for locally advanced or
metastatic gastric/gastroesophageal junction adenocarcinoma: Final
analysis of the randomized phase 2 FIGHT trial. Gastric Cancer.
27:558–570. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ornitz DM, Xu J, Colvin JS, McEwen DG,
MacArthur CA, Coulier F, Gao G and Goldfarb M: Receptor specificity
of the fibroblast growth factor family. J Biol Chem.
271:15292–15297. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang X, Ibrahimi OA, Olsen SK, Umemori H,
Mohammadi M and Ornitz DM: Receptor specificity of the fibroblast
growth factor family. The complete mammalian FGF family. J Biol
Chem. 281:15694–15700. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ornitz DM and Itoh N: The fibroblast
growth factor signaling pathway. Wiley Interdiscip Rev Dev Biol.
4:215–266. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nyeng P, Norgaard GA, Kobberup S and
Jensen J: FGF10 signaling controls stomach morphogenesis. Dev Biol.
303:295–310. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Speer AL, Al Alam D, Sala FG, Ford HR,
Bellusci S and Grikscheit TC: Fibroblast growth factor
10-fibroblast growth factor receptor 2b mediated signaling is not
required for adult glandular stomach homeostasis. PLoS One.
7:e491272012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ooi A, Oyama T, Nakamura R, Tajiri R,
Ikeda H, Fushida S, Nakamura H and Dobashi Y: Semi-comprehensive
analysis of gene amplification in gastric cancers using multiplex
ligation-dependent probe amplification and fluorescence in situ
hybridization. Mod Pathol. 28:861–871. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sun Q, Lin P, Zhang J, Li X, Yang L, Huang
J, Zhou Z, Liu P and Liu N: Expression of fibroblast growth factor
10 is correlated with poor prognosis in gastric adenocarcinoma.
Tohoku J Exp Med. 236:311–318. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Board WCoTE: Digestive System Tumours.
International Agency for Research on Cancer; Lyon: 2019
|
|
37
|
Brierley JD, Gospodarowicz MK and
Wittekind C: TNM Classification of Malignant Tumours. 8th edition.
Wiley-Blackwell; Hoboken: pp. 63–69. 2017
|
|
38
|
Altman DG, McShane LM, Sauerbrei W and
Taube SE: Reporting recommendations for tumor marker prognostic
studies (REMARK): Explanation and elaboration. PLoS Med.
9:e10012162012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Röcken C: Predictive biomarkers in gastric
cancer. J Cancer Res Clin Oncol. 149:467–481. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Watson J and Francavilla C: Regulation of
FGF10 signaling in development and disease. Front Genet. 9:5002018.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sankoda N, Tanabe W, Tanaka A, Shibata H,
Woltjen K, Chiba T, Haga H, Sakai Y, Mandai M, Yamamoto T, et al:
Epithelial expression of Gata4 and Sox2 regulates specification of
the squamous-columnar junction via MAPK/ERK signaling in mice. Nat
Commun. 12:5602021. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Abolhassani A, Riazi GH, Azizi E, Amanpour
S, Muhammadnejad S, Haddadi M, Zekri A and Shirkoohi R: FGF10: Type
III epithelial mesenchymal transition and invasion in breast cancer
cell lines. J Cancer. 5:537–547. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lv YQ, Wu J, Li XK, Zhang JS and Bellusci
S: Role of FGF10/FGFR2b signaling in mouse digestive tract
development, repair and regeneration following injury. Front Cell
Dev Biol. 7:3262019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Clayton NS and Grose RP: Emerging roles of
fibroblast growth factor 10 in cancer. Front Genet. 9:4992018.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ndlovu R, Deng LC, Wu J, Li XK and Zhang
JS: Fibroblast growth factor 10 in pancreas development and
pancreatic cancer. Front Genet. 9:4822018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Memarzadeh S, Xin L, Mulholland DJ,
Mansukhani A, Wu H, Teitell MA and Witte ON: Enhanced paracrine
FGF10 expression promotes formation of multifocal prostate
adenocarcinoma and an increase in epithelial androgen receptor.
Cancer Cell. 12:572–585. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Matsuike A, Ishiwata T, Watanabe M and
Asano G: Expression of fibroblast growth factor (FGF)-10 in human
colorectal adenocarcinoma cells. J Nippon Med Sch. 68:397–404.
2001. View Article : Google Scholar : PubMed/NCBI
|
